Sartorius agreed to acquire U.K.-based Albumedix, which develops and manufactures recombinant human albumin-based products. The acquisition confirms a general market shift towards fully defined and high-quality solutions for the manufacturing of advanced therapy products, in which recombinant human albumin is an essential component, according to Jonas S. Møller, Albumedix’s CEO.
Albumedix will become part of the bioprocess solutions division within Sartorius. “We believe Sartorius will bring tremendous value by strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform,” said Møller.
“Albumedix will be an important addition to Sartorius’ advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials,” added René Fáber, member of the executive Board for the bioprocess solutions division of Sartorius.
“This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones.
Under the terms of the agreement, Sartorius, through its French listed subgroup Sartorius Stedim Biotech, will acquire all outstanding shares of Albumedix for an agreed purchase price of approximately £415 million (about $503 million).